BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
Public ClinicalTrials.gov record NCT00528567. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main objective of the trial is to compare Invasive Disease-Free Survival (IDFS) of patients randomised to treatment with adjuvant chemotherapy alone or to adjuvant chemotherapy with 1 year of bevacizumab. The secondary objectives of this trial are to: * compare Overall Survival (OS), Breast Cancer-Free Interval (BCFI), Disease- Free Survival (DFS) and Distant Disease-Free Survival (DDFS) of patients randomised to treatment with adjuvant chemotherapy alone or to adjuvant chemotherapy in combination with 1 year of bevacizumab * evaluate the safety and tolerability of bevacizumab An exploratory sub-study (not reported here) was to identify biomarkers (from tumour or serum) predictive of toxicity and for the level of benefit from the addition of bevacizumab to standard adjuvant systemic treatment.
Study identification
- NCT ID
- NCT00528567
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,591 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2007 (Type not available)
- Primary completion
- Feb 2012 (Actual)
- Completion
- Jun 2014 (Actual)
- Last update posted
- Sep 4, 2015
2007 – 2014
United States locations
- U.S. sites
- 44
- U.S. states
- 21
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | 35805 | — |
| Not listed | Mobile | Alabama | 36604 | — |
| Not listed | Fayetteville | Arkansas | 72703 | — |
| Not listed | Bakersfield | California | 93309 | — |
| Not listed | Fountain Valley | California | 92708 | — |
| Not listed | Greenbrae | California | 94904 | — |
| Not listed | Los Angeles | California | 90057 | — |
| Not listed | Pleasant Hill | California | 94523 | — |
| Not listed | Fairfield | Connecticut | 06824 | — |
| Not listed | Stamford | Connecticut | 06902 | — |
| Not listed | Washington D.C. | District of Columbia | 20010 | — |
| Not listed | Gainesville | Florida | 32605 | — |
| Not listed | Orlando | Florida | 32806 | — |
| Not listed | Tamarac | Florida | 33321 | — |
| Not listed | Atlanta | Georgia | 30318 | — |
| Not listed | Augusta | Georgia | 30901 | — |
| Not listed | Lawrenceville | Georgia | 30046 | — |
| Not listed | Niles | Illinois | 60714 | — |
| Not listed | Iowa City | Iowa | 52242 | — |
| Not listed | Waterloo | Iowa | 50702 | — |
| Not listed | Baltimore | Maryland | 21215 | — |
| Not listed | Baltimore | Maryland | 21237 | — |
| Not listed | Rockville | Maryland | 20850-3348 | — |
| Not listed | Brownstown | Michigan | 48183 | — |
| Not listed | Kalamazoo | Michigan | 49007 | — |
| Not listed | Southfield | Michigan | 48075-3707 | — |
| Not listed | Kansas City | Missouri | 64111 | — |
| Not listed | St Louis | Missouri | 63141 | — |
| Not listed | Long Branch | New Jersey | 07740 | — |
| Not listed | The Bronx | New York | 10469 | — |
| Not listed | Hickory | North Carolina | 28602 | — |
| Not listed | Winston-Salem | North Carolina | 27103 | — |
| Not listed | Cincinnati | Ohio | 45242 | — |
| Not listed | Columbus | Ohio | 43235 | — |
| Not listed | Middletown | Ohio | 45042 | — |
| Not listed | Columbia | South Carolina | 29210 | — |
| Not listed | Chattanooga | Tennessee | 37404 | — |
| Not listed | Germantown | Tennessee | 38138 | — |
| Not listed | Nashville | Tennessee | 37203 | — |
| Not listed | Austin | Texas | 78759 | — |
| Not listed | Dallas | Texas | 75234 | — |
| Not listed | Rutland | Vermont | 05701 | — |
| Not listed | Abingdon | Virginia | 24211 | — |
| Not listed | Richmond | Virginia | 23230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 359 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00528567, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 4, 2015 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00528567 live on ClinicalTrials.gov.